Outcome of Board Meeting

Revenue Growth 20pctPat Growth 25pctRelated Party TransactionsResults View source PDF Explain this filing

KIMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-6.1%Reaction day

₹766.00

prior close

₹748.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-1.5%-4.7% vs market

Hospital peers, median of 25sector-0.5%-5.7% vs sector

On the reaction day the stock moved 4.7 pts less than Nifty Smallcap 250 and 5.7 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+0.2

15m

+0.3

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-6.1-1.5-4.7-0.5-5.7

Next day

-3.4-0.3-3.0+0.7-4.1

-2.3-0.3-2.1+0.2-2.6

+0.5+0.4+0.1+0.9-0.4

-1.0+0.3-1.3+0.3-1.3

-1.6+1.5-3.1+1.0-2.6

+2.4+2.3+0.1+0.1+2.3

15d

+2.0+1.5+0.4+2.4-0.4

+3.1+5.3-2.2+3.2-0.1

+3.3+7.8-4.5+5.0-1.7

+5.0+9.7-4.7+7.9-2.9

UpDownMarket · Nifty Smallcap 250Sector · Hospital peers, median of 25Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Krishna Institute of Medical Sciences (KIMS) board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026. Consolidated revenue grew 23.4% to Rs 16,120 million from Rs 13,065 million. Profit after tax increased 38.3% to Rs 2,395 million from Rs 1,732 million. The auditors S.R. Batliboi & Associates LLP issued an unmodified (clean) opinion. The board appointed M/s. Sagar & Associates as Cost Auditors for FY 2026-27 and made senior management changes including a new CFO and Company Secretary re-designation. Mr. Adwik Bollineni was re-designated from Non-Executive to Executive Director. The 24th AGM is scheduled for August 27, 2026.

Likely market impact

Strong financial performance with over 20% revenue growth and PAT growth exceeding 25% will be viewed positively by shareholders. Clean audit opinion and management changes provide stability. The company continues expanding with significant capital investments reflected in growing asset base.